MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hemonc.2015.06.005

Медицинская библиотека · Hematology/oncology and stem cell therapy · 2015

Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer.

Hamilton Betty Ky, Rybicki Lisa, Abounader Donna, Andresen Steven, Kalaycio Matt, Sobecks Ronald, Pohlman Brad, Hanna Rabi, Dean Robert, Liu Hien, Hill Brian, Bolwell Brian, Copelan Edward

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE/

BACKGROUND

The most common indication for high-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (AHCT) in the 1990s was breast cancer. Several randomized trials and a more recent meta-analysis failed to show a survival benefit for AHCT in metastatic breast cancer (MBC); however, they demonstrated a better-than-expected 10-year to 15-year survival in 5-15% of patients. We thus evaluated the long-term results of treatment with HDC and AHCT in MBC at our institution.

METHODS

From 1984 to 2000, 285 patients underwent AHCT for MBC. The patient characteristics were collected through the Cleveland Clinic, United Transplant Database. A retrospective review of the medical records of the long-term surviving breast-cancer patients treated with HDC and AHCT was conducted.

RESULTS

With a median follow-up of 169 months, 34 (12%) remain alive. Of the 251 patients who died, 218 (87%) died of metastatic disease. A comparison by age (<50 years and >50 years) and hormonal status did not demonstrate any differences in relapse (p=.33 and p=.32, respectively) or survival (p=.13 and p=.42). Of the 34 long-term survivors, sufficient data were available on 28 patients, and further evaluation revealed that the majority had a primary or locally recurrent oligometastatic disease.

CONCLUSION

This retrospective evaluation of patients who underwent AHCT for MBC demonstrates long-term survival in a small subset of patients, primarily those with primary or recurrent oligometastatic disease. Oligometastatic breast cancer is a distinct entity within MBC, which may be curable with multimodality therapy. We thus conclude there remains no overall-survival benefit to HDC in MBC.

Для цитирования: Hamilton Betty Ky, Rybicki Lisa, Abounader Donna, Andresen Steven, Kalaycio Matt, Sobecks Ronald, Pohlman Brad, Hanna Rabi, Dean Robert, Liu Hien, Hill Brian, Bolwell Brian, Copelan Edward. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer.. Hematology/oncology and stem cell therapy. 2015. DOI: 10.1016/j.hemonc.2015.06.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.